Bristol Myers Squibb ends partnership with Cellares, prompting the cell therapy maker to restructure

Bristol Myers Squibb announced that it is terminating its collaboration with Cellares after completing a comprehensive evaluation of the partnership.

The decision was driven by BMS’s assessment that the Cell Shuttle system and related development plans did not meet its strategic criteria.

Cellares said it will reorganize its operations in response to the termination, though it did not provide further details on the restructuring plan.